Migraine Unravelled: The Latest in Migraine Medication and Management Solutions

Join us for this FREE event! (Online Session available)

Migraine is a neurological condition that affects 1 in 7 people globally, and roughly 753,000 people in New Zealand live with this debilitating condition. Even with its widespread effect, migraine disease remains underdiagnosed and undertreated across Aotearoa.

Join us for a two-part event as we unravel the mysteries of migraine. Our first session will feature world-renowned Australian neuroscientist Professor Peter Goadsby, who will share what research reveals about the nature of migraine disease. Joining him is Professor Debbie Hay, a highly-cited researcher from the University of Otago, who will discuss the new wave of migraine medications.

Dr Calvin Chan, a neurologist and headache specialist, will lead a session on migraine management in New Zealand, to close the event. This will cover treatment, patient care, and challenges for healthcare providers in delivering effective care nationwide.

Don't miss this opportunity to hear from leading experts and discover new approaches to managing this debilitating condition.

This event is organised in partnership with the Neurological Foundation of New Zealand

Can't attend in person? An online option is available!
When registering for your ticket, select "Online Session."

About Our Speakers

	Professor Peter Goadsby Professor Goadsby is an Australian neuroscientist and physician based at King’s College London. He is the Director of the National Institute for Health Research - Wellcome Trust King’s Clinical Research. His research focuses on the mechanisms of primary headache disorders.              He was a co-recipient of the 2021 Brain prize for his work on the mechanisms and treatment of migraine disease and elected Fellow of the Royal Society in 2022.
	Professor Debbie Hay Professor Hay is a researcher at Otago University, Dunedin, leading a laboratory focusing on G protein coupled receptors, which are the target of drugs designed to treat migraine. Professor Hay obtained her BSc in pharmacology from Sheffield University, followed by her PhD from Imperial College London. She is an Editorial Board member of the British Journal of Pharmacology and member of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR), chairing its subcommittee on CGRP peptide family receptors.
	Dr Calvin Chan Dr Chan is a consultant neurologist and headache specialist in Palmerston North. He attained his medical degree from Otago University and worked in hospitals in Auckland, Waikato and Palmerston North. He completed a fellowship with Professor Goadsby’s Headache Group at King’s College London. On his return he has sat on the council of the Australian New Zealand Headache Society. He is uniquely placed to comment on the differences in headache medicine in the UK versus Aotearoa New Zealand and discuss how the standard of headache care can be improved in NZ.

Event Programme